Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common and dose-limiting side effect of cancer treatment. CIPN is characterized by impaired sensation, pain and occasionally motor dysfunction, resulting in significant physiological and psychological distress, and impaired quality of life. While rodent models have proven fundamental to the characterization of CIPN disease mechanisms, so far they have failed to yield clinically translatable therapies. Consequently, there are no proven prophylactic or curative treatments for the management of CIPN and only non-specific pain management strategies are currently in use. However, stem cell-based approaches to drug discovery may permit identification of medically relevant compounds. To develop more effective CIPN therapies, we are establishing an in vitro drug screening paradigm using human stem cell-derived peripheral sensory neurons. We aimed to optimize a protocol for the derivation of sensory neurons from human pluripotent stem cells; to characterize the derived cells using transcriptomic, protein and functional assays; and to optimize conditions for stem cell-derived sensory neuron culture and re-plating in preparation for future high throughput drug screening for identification of novel CIPN therapeutic targets.